
Opinion|Videos|September 16, 2024
BTK Inhibitor-Associated Adverse Events
The discussion explores the evolution of understanding adverse events (AEs) related to Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia treatment and identifies the primary classwide AEs associated with these therapies.
Advertisement
Episodes in this series

Now Playing
Video content above is prompted by the following:
- How has the understanding of adverse events associated with Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia treatment evolved, and what are the primary classwide adverse events?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
OpEd: The Drug Enforcement Administration Needs a Chief Pharmacy Officer. Here’s Why
2
FDA Approves Updated Indication for Upadacitinib in Patients With IBD
3
Pharmacy Policy Updates for October 2025
4
Inhaled Insulin Demonstrates Comparable Safety, Lung Function, and Efficacy to Injectable Insulin in Type 1 Diabetes
5